Overview

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the additional efficacy and safety of olmesartan medoxomil/hydrochlorothiazide in the treatment of Chinese patients with mild to moderate essential hypertension, who fail to attain the blood pressure goals with olmesartan medoxomil monotherapy

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Collaborator:

Shanghai Sankyo Pharmaceuticals Co., Ltd.

Treatments:

Hydrochlorothiazide
Olmesartan
Olmesartan Medoxomil